Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

B-cell lymphoma is a group of hematological malignancies with high clinical and biological
heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction …

Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment
modality where a patient's own T cells are collected and engineered ex vivo to express a …

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that
is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit …

The success of chimeric antigen receptor T cell (CAR-T) therapy in the treatment of
hematologic malignancies has prompted the development of numerous CAR-T …

Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy,
particularly with the success of CAR-T cells in treating hematologic malignancies. However …

Advancements in adoptive cell therapy over the last four decades have revealed various
new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated …

Canonical phototherapeutics have several limitations, including a lack of tumor selectivity,
nondiscriminatory phototoxicity, and tumor hypoxia aggravation. The tumor …

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21%
of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent …